COVID-19 Vaccine MVC-COV1901

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A vaccine composed of a recombinant form of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) combined with a synthetic CpG motif-based oligodeoxynucleotide (CpG ODN) vaccine adjuvant, CpG 1018, with potential immunomodulating and anti-COVID-19 activities. Upon administration of COVID-19 Vaccine MVC-COV1901, the SARS-CoV-2 SP activates the immune system to produce anti-SARS-CoV-2 SP antibodies and T-cell responses against SARS-CoV-2 SP. The antibodies recognize the SP and kill SARS-CoV-2. This prevents SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. The adjuvant strongly stimulates both T-cell and antibody immune responses when combined with the recombinant SARS-CoV-2 SP.

**Synonyms:** - MVC COV1901 - MVC-COV1901 - MVCCOV1901 - SARS-CoV-2 Spike Protein Plus Adjuvant CpG 1018 - SARS-CoV-2 Vaccine MVC-COV1901